Integra LifeSciences (NASDAQ:IART) Price Target Raised to $19.00

Integra LifeSciences (NASDAQ:IART) had its target price hoisted by Truist Financial from $14.00 to $19.00 in a research report report published on Thursday morning, MarketBeat.com reports. They currently have a hold rating on the life sciences company’s stock.

Several other equities analysts also recently weighed in on IART. Wall Street Zen raised Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 13th. Wells Fargo & Company raised their price target on Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research report on Thursday, June 18th. Finally, BMO Capital Markets assumed coverage on shares of Integra LifeSciences in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 target price on the stock. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $18.33.

Integra LifeSciences Stock Down 3.0%

Shares of NASDAQ:IART opened at $19.25 on Thursday. The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75. Integra LifeSciences has a 12 month low of $8.70 and a 12 month high of $20.26. The company has a 50-day moving average price of $16.91 and a 200 day moving average price of $13.08. The company has a market cap of $1.50 billion, a price-to-earnings ratio of -2.98, a PEG ratio of 1.33 and a beta of 1.22.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The company had revenue of $391.92 million for the quarter, compared to analysts’ expectations of $381.81 million. During the same period in the previous year, the firm posted $0.41 earnings per share. The firm’s revenue for the quarter was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, equities research analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Several hedge funds and other institutional investors have recently modified their holdings of the business. Global Retirement Partners LLC bought a new position in Integra LifeSciences in the 4th quarter valued at $25,000. Osaic Holdings Inc. lifted its position in shares of Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 1,104 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Integra LifeSciences by 145.9% during the fourth quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock valued at $78,000 after purchasing an additional 3,742 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Integra LifeSciences by 595.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after purchasing an additional 6,814 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of Integra LifeSciences in the fourth quarter worth about $124,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.